Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
life sciences
national blog main
national top stories
new york blog main
8
×
new york top stories
novartis
8
×
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
deals
medicare
merck
pfizer
abbvie
alzheimer's disease
cancer
clinical trials
diagnostics
drug prices
eli lilly
What
drug
8
×
bio
roundup
new
acquisitions
approval
biggest
brings
ceo
companies
company
fda
medicines
patients
pharmaceutical
plan
price
prices
today
acquire
advantages
agreed
albert
alzheimer’s
amgen
away
bar
billion
biogen’s
biopharmaceutical
bourla
bringing
build
buy
candidates
cash
ceos
cholesterol
class
company’s
Language
unset
unknown
Current search:
novartis
×
drug
×
" new york blog main "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines